The EDUCATE Study: Early Detection of recUrrence of CAncers of the brain using lateral flow TEsts

EDUCATE 研究：使用侧向流动测试早期检测脑癌复发

• 批准号: MR/Y008359/1
• 负责人: Philippe Wilson
• 金额: $ 6.16万
• 依托单位: Nottingham Trent University
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=MR%2FY008359%2F1
• 关键词: EDUCATE; Study; Early; Detection; recUrrence

In the UK, more than 2,500 people a year die from high-grade gliomas each year, rising to more than 190,000 people globally. The most aggressive of these have only a 12-15 month survival rate, with the tumours invariably recurring after treatment. The resurgence of the tumours is both unpredictable and highly irregular therefore the current 3-6 month MRI scans are often picking up this regrowth too late. The EDUCATE study (Early Detection of recUrrence of CAncers of the brain using lateral flow Tests) seeks to use the science behind work undertaken throughout the pandemic by the team, to develop a lateral flow test which can detect this tumour recurrence at the very early stages and thereby give patients the very best chance at treatment through far earlier intervention. We will do this through the 3 main arms of the EDUCATE study. Firstly, advanced lateral flow test (LFT) development will take place to detect these very early warning signs of recurring gliomas. We will use a range of the most recent technologies to find the smallest amounts of statistically significant biomarkers which can predict this tumour recurrence and offer patients a weekly testing opportunity. These LFTs will then be used as part of our blinded EDUCATE feasibility trial on patients at Sheffield Teaching Hospitals Trust to assess the cross-validation and implementation of this technology in a real-world and clinical setting. Finally, with the data gathered throughout the first two phases of the EDUCATE study, we will be in position to combine our understanding of these predictive biomarkers into a model which can also supplement current MRI scanning. This will add advanced information to the images seen by the clinicians and link that to our metabolic, genomic and transcriptomic data obtained in phases 1 and 2. The EDUCATE study will offer the first opportunity for at-home recurrence testing, dramatically increasing the early detection prospects for brain tumour recurrence with state-of-the-art lateral flow testing, and opening up further opportunities to widen this as a platform technology for cancers of unmet need more widely.

在英国，每年有2500多人死于高级别胶质瘤，全球死亡人数上升至19万多人。其中最具侵袭性的肿瘤只有12-15个月的存活率，治疗后肿瘤总是复发。肿瘤的复发是不可预测的，而且非常不规律，因此目前3-6个月的MRI扫描发现这种再生往往为时已晚。教育研究(早期检测脑癌复发使用横向血流测试)寻求利用团队在整个大流行期间所做工作背后的科学，开发一种横向血流测试，可以在非常早期阶段检测到这种肿瘤的复发，从而通过更早的干预为患者提供最好的治疗机会。我们将通过教育研究的三个主要分支来实现这一点。首先，将开发先进的侧向血流测试(LFT)来检测这些复发胶质瘤的非常早期的预警信号。我们将使用一系列最新的技术来寻找最小数量的统计上有意义的生物标记物，这些标记物可以预测这种肿瘤的复发，并为患者提供每周一次的检测机会。这些LFT随后将被用作谢菲尔德教学医院信托基金在患者身上进行的盲目教育可行性试验的一部分，以评估这项技术在现实世界和临床环境中的交叉验证和实施。最后，通过在教育研究的前两个阶段收集的数据，我们将能够将我们对这些预测性生物标志物的理解结合到一个模型中，该模型也可以补充当前的MRI扫描。这将为临床医生看到的图像添加先进的信息，并将这些信息与我们在第一阶段和第二阶段获得的新陈代谢、基因组和转录组数据联系起来。COREED研究将提供在家进行复发测试的第一次机会，通过最先进的侧向血流测试极大地提高脑瘤复发的早期检测前景，并打开进一步的机会，将其扩大为更广泛地满足未满足需求的癌症的平台技术。